A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor
Ovarian Cancer
DRUG: JPI-547
Objective Response Rate(ORR), To evaluate the objective response rate (ORR) in accordance with the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1., From date of study enroll until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months
Anti-tumor activity, To evaluate the anti-tumor activity in accordance with RECIST v1.1., From date of study enroll until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months
To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor